{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T14:46:22Z","timestamp":1778078782288,"version":"3.51.4"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T00:00:00Z","timestamp":1750636800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T00:00:00Z","timestamp":1750636800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Genet Genomics"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s00438-025-02273-3","type":"journal-article","created":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T15:55:29Z","timestamp":1750694129000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["GSK343, an inhibitor of EZH2, prevents acquired cisplatin resistance in bladder cancer"],"prefix":"10.1007","volume":"300","author":[{"given":"Liang","family":"He","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-7801-4247","authenticated-orcid":false,"given":"Peng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,6,23]]},"reference":[{"issue":"1","key":"2273_CR1","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.eururo.2023.08.016","volume":"85","author":"J Alfred Witjes","year":"2024","unstructured":"Alfred Witjes J, Max Bruins H, Carrion A, Cathomas R, Comperat E, Efstathiou JA, van der Heijden AG (2024) European association of urology guidelines on Muscle-invasive and metastatic bladder cancer: summary of the 2023 guidelines. Eur Urol 85(1):17\u201331. https:\/\/doi.org\/10.1016\/j.eururo.2023.08.016","journal-title":"Eur Urol"},{"issue":"5","key":"2273_CR2","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1021\/acsmedchemlett.5b00037","volume":"6","author":"JE Campbell","year":"2015","unstructured":"Campbell JE, Kuntz KW, Knutson SK, Warholic NM, Keilhack H, Wigle TJ, Copeland RA (2015) EPZ011989, A potent, Orally-Available EZH2 inhibitor with robust in vivo activity. ACS Med Chem Lett 6(5):491\u2013495. https:\/\/doi.org\/10.1021\/acsmedchemlett.5b00037","journal-title":"ACS Med Chem Lett"},{"key":"2273_CR3","doi-asserted-by":"publisher","unstructured":"Campolo M, Scuderi SA, Filippone A, Bova V, Lombardo SP, Colarossi L, Paterniti I (2024) EZH2 Inhibition to counteract oral Cancer progression through Wnt\/beta-Catenin pathway modulation. Pharmaceuticals (Basel) 17(8). https:\/\/doi.org\/10.3390\/ph17081102","DOI":"10.3390\/ph17081102"},{"key":"2273_CR4","doi-asserted-by":"publisher","first-page":"111063","DOI":"10.1016\/j.cellsig.2024.111063","volume":"116","author":"Y Cao","year":"2024","unstructured":"Cao Y, Sun H, Li X, Pommer W, Xiong Y, Chen X, Wang Z (2024) GSK343 modulates macrophage M2 polarization through the EZH2\/MST1\/YAP1 signaling axis to mitigate neurological damage induced by hypercalcemia in CKD mice. Cell Signal 116:111063. https:\/\/doi.org\/10.1016\/j.cellsig.2024.111063","journal-title":"Cell Signal"},{"issue":"11","key":"2273_CR5","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1038\/ncb2116","volume":"12","author":"S Chen","year":"2010","unstructured":"Chen S, Bohrer LR, Rai AN, Pan Y, Gan L, Zhou X, Huang H (2010) Cyclin-dependent kinases regulate epigenetic gene Silencing through phosphorylation of EZH2. Nat Cell Biol 12(11):1108\u20131114. https:\/\/doi.org\/10.1038\/ncb2116","journal-title":"Nat Cell Biol"},{"issue":"1","key":"2273_CR6","doi-asserted-by":"publisher","first-page":"907","DOI":"10.3892\/ol.2019.10359","volume":"18","author":"Z Chen","year":"2019","unstructured":"Chen Z, Du Y, Liu X, Chen H, Weng X, Guo J, Wang L (2019) EZH2 Inhibition suppresses bladder cancer cell growth and metastasis via the JAK2\/STAT3 signaling pathway. Oncol Lett 18(1):907\u2013915. https:\/\/doi.org\/10.3892\/ol.2019.10359","journal-title":"Oncol Lett"},{"issue":"10364","key":"2273_CR7","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.1016\/S0140-6736(22)01188-6","volume":"400","author":"E Comperat","year":"2022","unstructured":"Comperat E, Amin MB, Cathomas R, Choudhury A, De Santis M, Kamat A, Witjes JA (2022) Current best practice for bladder cancer: a narrative review of diagnostics and treatments. Lancet 400(10364):1712\u20131721. https:\/\/doi.org\/10.1016\/S0140-6736(22)01188-6","journal-title":"Lancet"},{"issue":"1","key":"2273_CR8","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/s1040-8428(01)00128-7","volume":"41","author":"F de Braud","year":"2002","unstructured":"de Braud F, Maffezzini M, Vitale V, Bruzzi P, Gatta G, Hendry WF, Sternberg CN (2002) Bladder cancer. Crit Rev Oncol Hematol 41(1):89\u2013106. https:\/\/doi.org\/10.1016\/s1040-8428(01)00128-7","journal-title":"Crit Rev Oncol Hematol"},{"issue":"1","key":"2273_CR9","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s13045-020-00937-8","volume":"13","author":"R Duan","year":"2020","unstructured":"Duan R, Du W, Guo W (2020) EZH2: a novel target for cancer treatment. J Hematol Oncol 13(1):104. https:\/\/doi.org\/10.1186\/s13045-020-00937-8","journal-title":"J Hematol Oncol"},{"issue":"1","key":"2273_CR10","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1038\/s41572-023-00468-9","volume":"9","author":"L Dyrskjot","year":"2023","unstructured":"Dyrskjot L, Hansel DE, Efstathiou JA, Knowles MA, Galsky MD, Teoh J, Theodorescu D (2023) Bladder cancer. Nat Rev Dis Primers 9(1):58. https:\/\/doi.org\/10.1038\/s41572-023-00468-9","journal-title":"Nat Rev Dis Primers"},{"issue":"1","key":"2273_CR11","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1186\/s12885-020-07667-7","volume":"20","author":"H Gong","year":"2020","unstructured":"Gong H, Li Y, Yuan Y, Li W, Zhang H, Zhang Z, Chen J (2020) EZH2 inhibitors reverse resistance to gefitinib in primary EGFR wild-type lung cancer cells. BMC Cancer 20(1):1189. https:\/\/doi.org\/10.1186\/s12885-020-07667-7","journal-title":"BMC Cancer"},{"key":"2273_CR12","doi-asserted-by":"publisher","unstructured":"Huang EY, Chen YK, Ou CP, Chen YT, Chen SF, Huang WJ, Liang KH (2022) Oncogenic roles of polycomb repressive complex 2 in bladder Cancer and upper tract urothelial carcinoma. Biomedicines 10(11). https:\/\/doi.org\/10.3390\/biomedicines10112925","DOI":"10.3390\/biomedicines10112925"},{"key":"2273_CR13","doi-asserted-by":"publisher","first-page":"216706","DOI":"10.1016\/j.canlet.2024.216706","volume":"586","author":"P Kaur","year":"2024","unstructured":"Kaur P, Shankar E, Gupta S (2024) EZH2-mediated development of therapeutic resistance in cancer. Cancer Lett 586:216706. https:\/\/doi.org\/10.1016\/j.canlet.2024.216706","journal-title":"Cancer Lett"},{"issue":"11","key":"2273_CR14","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1038\/nchembio.1084","volume":"8","author":"SK Knutson","year":"2012","unstructured":"Knutson SK, Wigle TJ, Warholic NM, Sneeringer CJ, Allain CJ, Klaus CR, Kuntz KW (2012) A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells. Nat Chem Biol 8(11):890\u2013896. https:\/\/doi.org\/10.1038\/nchembio.1084","journal-title":"Nat Chem Biol"},{"key":"2273_CR15","doi-asserted-by":"publisher","unstructured":"Kolawa A, D\u2019Souza A, Tulpule V (2023) Overview, diagnosis, and perioperative systemic therapy of upper tract urothelial carcinoma. Cancers (Basel) 15(19). https:\/\/doi.org\/10.3390\/cancers15194813","DOI":"10.3390\/cancers15194813"},{"issue":"3","key":"2273_CR16","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1021\/acs.jmedchem.7b01375","volume":"61","author":"PP Kung","year":"2018","unstructured":"Kung PP, Bingham P, Brooun A, Collins M, Deng YL, Dinh D, Edwards M (2018) Optimization of orally bioavailable enhancer of Zeste homolog 2 (EZH2) inhibitors using ligand and Property-Based design strategies: identification of development candidate (R)-5,8-Dichloro-7-(methoxy(oxetan-3-yl)methyl)-2-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-3,4-dihydroisoquinolin-1(2H)-one (PF-06821497). J Med Chem 61(3):650\u2013665. https:\/\/doi.org\/10.1021\/acs.jmedchem.7b01375","journal-title":"J Med Chem"},{"key":"2273_CR17","doi-asserted-by":"publisher","unstructured":"Ler LD, Ghosh S, Chai X, Thike AA, Heng HL, Siew EY, Teh BT (2017) Loss of tumor suppressor KDM6A amplifies PRC2-regulated transcriptional repression in bladder cancer and can be targeted through Inhibition of EZH2. Sci Transl Med 9(378). https:\/\/doi.org\/10.1126\/scitranslmed.aai8312","DOI":"10.1126\/scitranslmed.aai8312"},{"key":"2273_CR18","doi-asserted-by":"publisher","first-page":"100938","DOI":"10.1016\/j.drup.2023.100938","volume":"68","author":"F Li","year":"2023","unstructured":"Li F, Zheng Z, Chen W, Li D, Zhang H, Zhu Y, Tan W (2023) Regulation of cisplatin resistance in bladder cancer by epigenetic mechanisms. Drug Resist Updat 68:100938. https:\/\/doi.org\/10.1016\/j.drup.2023.100938","journal-title":"Drug Resist Updat"},{"issue":"6","key":"2273_CR21","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s12032-023-02025-6","volume":"40","author":"Y Liu","year":"2023","unstructured":"Liu Y, Yang Q (2023) The roles of EZH2 in cancer and its inhibitors. Med Oncol 40(6):167. https:\/\/doi.org\/10.1007\/s12032-023-02025-6","journal-title":"Med Oncol"},{"issue":"2","key":"2273_CR20","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1097\/CAD.0000000000000166","volume":"26","author":"TP Liu","year":"2015","unstructured":"Liu TP, Lo HL, Wei LS, Hsiao HH, Yang PM (2015) S-Adenosyl-L-methionine-competitive inhibitors of the histone methyltransferase EZH2 induce autophagy and enhance drug sensitivity in cancer cells. Anticancer Drugs 26(2):139\u2013147. https:\/\/doi.org\/10.1097\/CAD.0000000000000166","journal-title":"Anticancer Drugs"},{"issue":"1","key":"2273_CR19","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s12943-021-01369-9","volume":"20","author":"L Liu","year":"2021","unstructured":"Liu L, Cui J, Zhao Y, Liu X, Chen L, Xia Y, Zou Y (2021) KDM6A-ARHGDIB axis blocks metastasis of bladder cancer by inhibiting Rac1. Mol Cancer 20(1):77. https:\/\/doi.org\/10.1186\/s12943-021-01369-9","journal-title":"Mol Cancer"},{"issue":"6","key":"2273_CR22","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1158\/1535-7163.MCT-09-0013","volume":"8","author":"TB Miranda","year":"2009","unstructured":"Miranda TB, Cortez CC, Yoo CB, Liang G, Abe M, Kelly TK, Jones PA (2009) DZNep is a global histone methylation inhibitor that reactivates developmental genes not silenced by DNA methylation. Mol Cancer Ther 8(6):1579\u20131588. https:\/\/doi.org\/10.1158\/1535-7163.MCT-09-0013","journal-title":"Mol Cancer Ther"},{"issue":"4","key":"2273_CR23","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1038\/s41417-024-00725-3","volume":"31","author":"G Ozgun","year":"2024","unstructured":"Ozgun G, Yaras T, Akman B, Ozden-Yilmaz G, Landman N, Karakulah G, Erkek-Ozhan S (2024) Retinoids and EZH2 inhibitors cooperate to orchestrate anti-oncogenic effects on bladder cancer cells. Cancer Gene Ther 31(4):537\u2013551. https:\/\/doi.org\/10.1038\/s41417-024-00725-3","journal-title":"Cancer Gene Ther"},{"issue":"40","key":"2273_CR24","doi-asserted-by":"publisher","first-page":"eabo8043","DOI":"10.1126\/sciadv.abo8043","volume":"8","author":"A Piunti","year":"2022","unstructured":"Piunti A, Meghani K, Yu Y, Robertson AG, Podojil JR, McLaughlin KA, Meeks JJ (2022) Immune activation is essential for the antitumor activity of EZH2 Inhibition in urothelial carcinoma. Sci Adv 8(40):eabo8043. https:\/\/doi.org\/10.1126\/sciadv.abo8043","journal-title":"Sci Adv"},{"issue":"4","key":"2273_CR25","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1158\/1535-7163.MCT-21-0216","volume":"21","author":"SEJ Preston","year":"2022","unstructured":"Preston SEJ, Emond A, Pettersson F, Dupere-Richer D, Abraham MJ, Riva A, Miller WH (2022) Acquired resistance to EZH2 inhibitor GSK343 promotes the differentiation of human DLBCL cell lines toward an ABC-Like phenotype. Mol Cancer Ther 21(4):511\u2013521. https:\/\/doi.org\/10.1158\/1535-7163.MCT-21-0216","journal-title":"Mol Cancer Ther"},{"key":"2273_CR26","doi-asserted-by":"publisher","unstructured":"Rehman H, Chandrashekar DS, Balabhadrapatruni C, Nepal S, Balasubramanya SAH, Shelton AK, Ferguson JE 3rd (2022) ARID1A-deficient bladder cancer is dependent on PI3K signaling and sensitive to EZH2 and PI3K inhibitors. JCI Insight 7(16). https:\/\/doi.org\/10.1172\/jci.insight.155899","DOI":"10.1172\/jci.insight.155899"},{"issue":"2","key":"2273_CR27","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1038\/s41416-022-02058-0","volume":"128","author":"J Ren","year":"2023","unstructured":"Ren J, Yu H, Li W, Jin X, Yan B (2023) Downregulation of CBX7 induced by EZH2 upregulates FGFR3 expression to reduce sensitivity to cisplatin in bladder cancer. Br J Cancer 128(2):232\u2013244. https:\/\/doi.org\/10.1038\/s41416-022-02058-0","journal-title":"Br J Cancer"},{"key":"2273_CR28","doi-asserted-by":"publisher","unstructured":"Samarzija I, Tomljanovic M, Kujundzic N, R., Troselj KG (2022) EZH2 Inhibition and cisplatin as a combination anticancer therapy: an overview of preclinical studies. Cancers (Basel) 14(19). https:\/\/doi.org\/10.3390\/cancers14194761","DOI":"10.3390\/cancers14194761"},{"key":"2273_CR29","doi-asserted-by":"publisher","unstructured":"Scuderi SA, Filippone A, Basilotta R, Mannino D, Casili G, Capra AP, Paterniti I (2022) GSK343, an inhibitor of enhancer of Zeste homolog 2, reduces glioblastoma progression through inflammatory process modulation: focus on canonical and Non-Canonical NF-kappaB\/IkappaBalpha pathways. Int J Mol Sci 23(22). https:\/\/doi.org\/10.3390\/ijms232213915","DOI":"10.3390\/ijms232213915"},{"issue":"7","key":"2273_CR30","doi-asserted-by":"publisher","first-page":"e493","DOI":"10.1016\/S2352-3026(22)00134-X","volume":"9","author":"Y Song","year":"2022","unstructured":"Song Y, Liu Y, Li ZM, Li L, Su H, Jin Z, Zhu J (2022) SHR2554, an EZH2 inhibitor, in relapsed or refractory mature lymphoid neoplasms: a first-in-human, dose-escalation, dose-expansion, and clinical expansion phase 1 trial. Lancet Haematol 9(7):e493\u2013e503. https:\/\/doi.org\/10.1016\/S2352-3026(22)00134-X","journal-title":"Lancet Haematol"},{"issue":"6","key":"2273_CR31","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1038\/onc.2013.604","volume":"34","author":"C Vallot","year":"2015","unstructured":"Vallot C, Herault A, Boyle S, Bickmore WA, Radvanyi F (2015) PRC2-independent chromatin compaction and transcriptional repression in cancer. Oncogene 34(6):741\u2013751. https:\/\/doi.org\/10.1038\/onc.2013.604","journal-title":"Oncogene"},{"issue":"5","key":"2273_CR32","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1038\/s41571-023-00744-3","volume":"20","author":"LMC van Hoogstraten","year":"2023","unstructured":"van Hoogstraten LMC, Vrieling A, van der Heijden AG, Kogevinas M, Richters A, Kiemeney LA (2023) Global trends in the epidemiology of bladder cancer: challenges for public health and clinical practice. Nat Rev Clin Oncol 20(5):287\u2013304. https:\/\/doi.org\/10.1038\/s41571-023-00744-3","journal-title":"Nat Rev Clin Oncol"},{"issue":"40","key":"2273_CR33","doi-asserted-by":"publisher","first-page":"6265","DOI":"10.1038\/s41388-019-0902-7","volume":"39","author":"V Vantaku","year":"2020","unstructured":"Vantaku V, Putluri V, Bader DA, Maity S, Ma J, Arnold JM, Putluri N (2020) Epigenetic loss of AOX1 expression via EZH2 leads to metabolic deregulations and promotes bladder cancer progression. Oncogene 39(40):6265\u20136285. https:\/\/doi.org\/10.1038\/s41388-019-0902-7","journal-title":"Oncogene"},{"issue":"12","key":"2273_CR34","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1021\/ml3003346","volume":"3","author":"SK Verma","year":"2012","unstructured":"Verma SK, Tian X, LaFrance LV, Duquenne C, Suarez DP, Newlander KA, Miller WH (2012) Identification of potent, selective, Cell-Active inhibitors of the histone lysine methyltransferase EZH2. ACS Med Chem Lett 3(12):1091\u20131096. https:\/\/doi.org\/10.1021\/ml3003346","journal-title":"ACS Med Chem Lett"},{"issue":"15","key":"2273_CR35","doi-asserted-by":"publisher","first-page":"7408","DOI":"10.18632\/aging.204863","volume":"15","author":"Y Wang","year":"2023","unstructured":"Wang Y, Zhu H, Xu H, Qiu Y, Zhu Y, Wang X (2023) Senescence-related gene c-Myc affects bladder cancer cell senescence by interacting with HSP90B1 to regulate cisplatin sensitivity. Aging 15(15):7408\u20137423. https:\/\/doi.org\/10.18632\/aging.204863","journal-title":"Aging"},{"issue":"3","key":"2273_CR36","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1080\/15384047.2019.1680061","volume":"21","author":"X Xiong","year":"2020","unstructured":"Xiong X, Zhang J, Li A, Dai L, Qin S, Wang P, Liu Z (2020) GSK343 induces programmed cell death through the Inhibition of EZH2 and FBP1 in osteosarcoma cells. Cancer Biol Ther 21(3):213\u2013222. https:\/\/doi.org\/10.1080\/15384047.2019.1680061","journal-title":"Cancer Biol Ther"},{"issue":"24","key":"2273_CR37","doi-asserted-by":"publisher","first-page":"7331","DOI":"10.1158\/1078-0432.CCR-18-4121","volume":"25","author":"TA Yap","year":"2019","unstructured":"Yap TA, Winter JN, Giulino-Roth L, Longley J, Lopez J, Michot JM, Johnson PWM (2019) Phase I study of the novel enhancer of Zeste homolog 2 (EZH2) inhibitor GSK2816126 in patients with advanced hematologic and solid tumors. Clin Cancer Res 25(24):7331\u20137339. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-4121","journal-title":"Clin Cancer Res"},{"issue":"58","key":"2273_CR38","doi-asserted-by":"publisher","first-page":"98348","DOI":"10.18632\/oncotarget.21311","volume":"8","author":"T Yu","year":"2017","unstructured":"Yu T, Wang Y, Hu Q, Wu W, Wu Y, Wei W, Liu N (2017) The EZH2 inhibitor GSK343 suppresses cancer stem-like phenotypes and reverses mesenchymal transition in glioma cells. Oncotarget 8(58):98348\u201398359. https:\/\/doi.org\/10.18632\/oncotarget.21311","journal-title":"Oncotarget"},{"key":"2273_CR39","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1186\/s12935-020-01260-5","volume":"20","author":"R Zhang","year":"2020","unstructured":"Zhang R, Li X, Liu Z, Wang Y, Zhang H, Xu H (2020) EZH2 inhibitors-mediated epigenetic reactivation of FOSB inhibits triple-negative breast cancer progress. Cancer Cell Int 20:175. https:\/\/doi.org\/10.1186\/s12935-020-01260-5","journal-title":"Cancer Cell Int"},{"issue":"1","key":"2273_CR40","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1038\/s41594-024-01391-7","volume":"32","author":"Y Zhang","year":"2025","unstructured":"Zhang Y, Chen K, Tang SC, Cai Y, Nambu A, See YX, Fullwood MJ (2025) Super-silencer perturbation by EZH2 and REST Inhibition leads to large loss of chromatin interactions and reduction in cancer growth. Nat Struct Mol Biol 32(1):137\u2013149. https:\/\/doi.org\/10.1038\/s41594-024-01391-7","journal-title":"Nat Struct Mol Biol"},{"key":"2273_CR41","doi-asserted-by":"publisher","first-page":"e18871","DOI":"10.7717\/peerj.18871","volume":"13","author":"Z Zhao","year":"2025","unstructured":"Zhao Z, Chen X, Pang H, Shi Y, Sun H (2025) Safety profile of EZH2 inhibitors for cancer: a systematic review and meta-analysis. PeerJ 13:e18871. https:\/\/doi.org\/10.7717\/peerj.18871","journal-title":"PeerJ"}],"container-title":["Molecular Genetics and Genomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00438-025-02273-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00438-025-02273-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00438-025-02273-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T15:55:30Z","timestamp":1750694130000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00438-025-02273-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,23]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["2273"],"URL":"https:\/\/doi.org\/10.1007\/s00438-025-02273-3","relation":{},"ISSN":["1617-4615","1617-4623"],"issn-type":[{"value":"1617-4615","type":"print"},{"value":"1617-4623","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,23]]},"assertion":[{"value":"22 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study did not involve human or animal subjects, and thus, no ethical approval was required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"No conflict of interest is declared by the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"63"}}